ORTHOWORLD's preliminary estimates place overall 2011 market growth at 5% over 2010, as displayed in Exhibit 1. Performance highlights follow, and address both 4Q11 and 2011, as indicated.
Orthopaedic Sales1 Increases by Product Segment: 2011 vs. 2010
Notes to Exhibit 1:
1. Orthopaedic products except as indicated; constant currency, pro forma growth
2. For the quarter ended 11/30/11; Includes Dental. Spine includes Bone Stim and Biologics; Bone Stim reflects all Bone Healing sales.
3. For the quarter ended 12/31/11
4. Extremities: extremities + fixation combined; Endoscopy: endoscopic + communications, most of which is orthopaedic; Spine: neuro + spine. Total growth excludes Patient Handling.
5. ORTHOWORLD estimates
6. For the quarter ended 12/31/11
SEK 18.3MM (~US $2.7MM), -1%
4Q11 revenue: SEK 4MM ($0.6MM), +14%
- 12/11 represented best performance ever for sales of own products in U.S.
- In 1Q, resumed responsibility for sales of Artelon CMC Spacer, previously handled by Small Bone Innovations
- Assumed direct sales of own products on Nordic market
$5,809MM, +1%* (U.S. $3,093MM, -2%%; ex-U.S. $2,716MM, +5%) (Growth by segment not available for full year)
4Q11 revenue: $1,453MM, +0.3% (U.S. $775MM, -4%; ex-U.S. $678MM, +6%)
Hips +1% (U.S. flat, ex-U.S. +3%)
Knees -3% (U.S. -5%, ex-U.S. flat)
Spine -3% (U.S. -7%, ex-U.S. +4%)
*DePuy sales do not reflect purely orthopaedic revenue.
- Adjusting business segments: Global Orthopaedic will comprise DePuy and Synthes (following close of acquisition)
- Low single-digit price erosion, partially offset by positive mix
- Ex-U.S. hip growth from heads, cementless stems
- Strong sports med sales partially offset by lower knee, spine sales